Jeil Pharmaceutical's 37th domestic new drug for the treatment of gastroesophageal reflux disease, Jacubo, has kicked off its marketing activities ahead of its launch.
Jeil Pharmaceutical announced on the 15th that from the 12th to the 13th, over 400 domestic sales and marketing employees, including President Seong Seok-je, participated in the Jacubo POA (Plan of Action) held in Seoul and Daegu.
During this POA, the value of Jacubo as a new solution for the treatment of gastroesophageal reflux disease was discussed, and through various topic discussions, strategies and ideas considering actual sales field situations were shared. POA serves as a role for pharmaceutical and bio companies to provide education to sales and marketing personnel, enhance understanding and field execution capabilities, and deliver key information.
Jacubo is a next-generation potassium-competitive acid blocker (P-CAB) drug that is replacing existing proton pump inhibitors (PPIs) in the peptic ulcer drug market. It is the 37th domestic new drug and received product approval from the Ministry of Food and Drug Safety in April. It is expected to be launched within the year after being listed on the national health insurance reimbursement. Jeil Pharmaceutical is accelerating research and development (R&D) to expand indications not only for erosive gastroesophageal reflux disease treatment but also for various indications including gastric ulcers.
A Jeil Pharmaceutical official said, "This POA was a meaningful opportunity to share the sales strategy and goals for Jacubo," adding, "Based on differentiated data proven through clinical trials, we will provide new treatment options to medical professionals and patients, and quickly target the market through competitive sales and marketing activities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
